Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of iluzanebart (VGL101) in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia
NL-OMON60749Phase 3Completed
- Sponsor
- Vigil Neuroscience
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of iluzanebart in CSF1R-related leukoencephalopathy (ALSP), sponsored by Vigil Neuroscience. Primary endpoint: Safety and tolerability. Started Aug 2023; status: completed.
02
Drugs
iluzanebart
03
Conditions
CSF1R-related leukoencephalopathy (ALSP)
Beyond the preview
Go deeper on NL-OMON60749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60749.